Cardiol Therapeutics Inc. (CRDL) Research

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

Market snapshot

Symbol
CRDL
Price
$1.06
Day change
0.00%
Market cap
$172.9M
P/E ratio
-4.50x
52-week range
0.88-1.71
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months
Analyst price target
$8.00

Peer companies

  • Assertio Holdings, Inc. (ASRT)
  • Connect Biopharma Holdings Limited (CNTB)
  • Hyperfine, Inc. (HYPR)
  • InflaRx N.V. (IFRX)
  • ImageneBio Inc (IMA)
  • InterCure Ltd. (INCR)
  • Kalaris Therapeutics Inc (KLRS)
  • Microbot Medical Inc. (MBOT)

Open Cardiol Therapeutics Inc. (CRDL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.